Modern Tek News on KZSU, Stanford 90.1 FM
We will interview Professor Irv Weissman about the potential of using stem cells in treating many diseases and revolutionizing medicine in a wonderful way over the next few years. Professor Weissman discussed the new cancer trials for anti CD47 antibodies which is designed to help test if stem cells could cure all kinds of cancer. Professor Weissman also discussed other clinical trials that will test if stem cells can treat alzheimers, diabetes, macular degeneration and other diseases . Professor Theodore Leng is leading Stanford University's clinical trial for exploring the treatment of macular degeneration with stem cells.
This interview was broadcast on KZSU in November, 2013 and can be downloaded from this link .
Dr. Theodore Leng's section of the interview about Macular Degeneration's Treatment by Stem Cells
Our interview with Professor Bruce Buckingham was broadcast on November 6, 2013 and can be downloaded from this link. In this interview Dr. Buckingham discussed the research work and clinical trials on the Artificial Pancreas, the joint trial at Stanford to test the Bionic Pancreas with Boston University, in the summer of 2014 and the new trials by Professor Wilson on delaying the onset of diabetes in high risk groups. For more information about these trials, please visit their website. Robert Klein, who conceived of and led the campaign for Proposition 71 which created California's Stem Cell Agency, gave KZSU an interview about the success of the stem cell research in California. Mr. Klein talked about some of the stem cell clinical trials that are under way to find cures for cancer, heart disease, diabetes, epilepsy, macular degeneration, ALS and other diseases. To find out more these clinical trials, please visit California Institute for Regenerative Medicine. Mr. Klein also discussed how the Americans for Cures Foundation plans to work with the public to advance stem cell research in the future. This interview will be broadcast on KZSU in May, 2014 and is available from this link. Dr. Eduardo Marbán, Director Cedars-Sinai Heart Institute discussed the current Phase 2 Heart Stem Cell Clinical Trials at Cedars-Sinai which are underway in 2014. Dr. Marbán described how Phase 1 Clinical trial showed that heart stem cells can help repair heart tissue damaged during heart attacks. Cedars-Sinai is leading the effort for the Phase 2 ALLSTAR Clinical Trial. If patients would like more information about the trial, Dr. Marbán suggested they visit the Capricor Therapeutics, the biotech company that is in charge of this study. We also talked about why not many women are included in clinical trials associated with heart disease and how the Barbara Streisand Women's Heart Center at Cedars-Sinai is planning to change that. This interview was broadcast on KZSU in June, 2014. It can be downloaded from this link.
We bring you the latest stem cell and medical research news!
Dr. Joseph Wu discussed his lab's research on Cardiac iPS Cells (iPSC) and how they are pioneering an iPSC Biobank where patients can store their stem cells. These stem cells would be used to help treat genetic heart disease and could also be used for drug screening and discovery. Dr. Wu said that they initially need 1,000 volunteers to donate only 10 cc of blood each so that they could have initial data for the iPSC biobank. Dr. Wu added that the 1,000 limit is a number restricted by the current funding level for the project. In the second part of the interview Dr. Wu discussed how his lab's research on the iPSCs will impact personalized medicine in the next few years. At the end of the interview, listeners will find out how high school students can volunteer to work at the Wu Lab and other science labs at Stanford. This interview was broadcast on KZSU in August, 2014. It can be downloaded from this link. KZSU interviewed Harvard Professor Kwang-Soo Kim about his recent landmark paper (published in PNAS) in which he showed that 2 FDA approved drugs: Chloroquine and Amodiaquine cured mice who have Parkinson’s disease. The last phase of the research was done in collaboration with Professor Yoon Ho Sup at NTU , Singapore. The NTU team used NMR techniques to prove and show that Chloroquine molecules bound to the brain’s Nuur1 protein and so helped cure the mice with Parkinson’s. Professor Kim, who is also the Director of the Molecular Neurobiology Lab at McLean Hospital, described how he has worked for more than 25 years to find a cure for Parkinson’s, He said that he and his team were lucky to find that the structure of Chloroquine and Amodiaquine helped to cure the mice with Parkinson’s, However, Professor Kim added that he believes that better drugs can be designed to help cure Parkinson’s. He envisions that these new drugs would have the same structure as Chloroquine and be safer for Parkinson’s patients . That is not to say that Chlorquine is not safe: it has been approved by the FDA as an antimalarial and has also been used to treat Lupus and Rheumatoid Arthritis.
Professor Kim mentioned that the new drugs could possibly be designed to also treat other diseases that affect the middle part of our brains. In the interview Professor Kim also discussed how his team, if they find funding, might start a Phase 1 Clinical Trial to test the effectiveness of using Chloroquine to treat Parkinson’s in humans.
KZSU broadcast this interview in July, 2015; it is available from this link.
Can VC-01, Viacyte's New Stem Cell Based Device, Treat Diabetes Type 1?
Viacyte developed VC-01 after more than 15 years of research on using stem cell technology to treat Diabetes Type 1. VC-01 is now in clinical trials in the US and Canada to test if it's stem cell therapy can help treat Diabetes Type 1. In his interview with KZSU, Dr. Laikind discussed how VC-01 works, how this technology has cured diabetes in the animal model, how VC-01 might help treat patients with Type 1 Diabetes and how to find out about the clinical trials of VC-01. Dr. Laikind described how Viacyte started and became the leader in the field of stem cell technology for treating Diabetes; Viactye holds over 100 patents in this research, with over 150 patents pending as of March, 2014. Dr. Laikind also discussed how JDRF and the California Institute for Regenerative Medicine (CIRM) have helped fund some of the work that went into making VC-01 successful so far. This interview was broadcast on KZSU on December 9, 2015 and is available from this link.